Ovarian CancerGC-BIONCT01977274
Predictive Clinical and Biological Parameters in Gynecological Cancer
A study testing gynecological cancer in people with Ovarian Cancer and Endometrium Cancer, run by Institut Paoli-Calmettes at 1 site in France.
Trial summary
Research of predictive clinical and biological factors in breast cancer : genomic, proteomic, mutation Read more about this study
- Who is it for?
- Ages 18 years and older, women only
- Conditions the study is for
- Ovarian Cancer, Endometrium Cancer, Cervix Cancer
- What is being tested?
- gynecological cancer
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 300 participants
- Where
- 1 siteFrance
- Study dates
- Dec 2013to Dec 2035
- Phase
- Interventional
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- Women only
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- gynecological cancer suspicion
- age > 18
- signed informed consent
Who cannot join
- emergency
- Exclusion criteria after histological exam Any diagnosis that is not a gynecological cancer (ovarian, cervix, endometrium).
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Predictive Clinical and Biological Parameters in Gynecological Cancer - GC-BIO-IPC 2013-010
Research of predictive clinical and biological factors in breast cancer : genomic, proteomic, mutation
- Conditions
- Ovarian Cancer, Endometrium Cancer, Cervix Cancer
- Being tested
- gynecological cancer
- Keywords
- ovarian, endometrium, cervix cancer
- Medical subject headings
- Ovarian Neoplasms, Endometrial Neoplasms, Uterine Cervical Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
gynecological cancerOther
blood and tumor samples
| Study group | Role | What they receive |
|---|---|---|
| gynecological cancer | Experimental | blood and tumor samples Receives: Other: gynecological cancer |
What is being measured
The primary outcome is the main question the study is designed to answer.
molecular alteration in gynecological cancer
gene expression level
Measured: average of 4 weeks after diagnosis
Secondary outcomes (1)
relation between molecular alteration and clinical and histological characteristics
hazard ratio between molecular alteration and clinico-histological characteristics
Measured: up to 10 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted6 Nov 2013 (estimated)
- Study startDec 2013
- Primary completionDec 2033 (estimated)
- Study completionDec 2035 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Ovarian CancerStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Basic science
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 300 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Institut Paoli-Calmettes
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01977274
- Sponsor's protocol ID
- GC-BIO-IPC 2013-010
- Acronym
- GC-BIO
- Status last verified
- Mar 2026
- First submitted
- 30 Oct 2013
- Last updated
- 31 Mar 2026
- Results posted
- No
- Data monitoring committee
- No